文献速递腹部介入MR

经导管动脉化疗栓塞治疗神经内分泌肿瘤肝转移的肿瘤反应影像生物标志物:全肝强化肿瘤负荷能否帮助预测患者生存

Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
PubMed 文献 · Radiology · 2016-11-10

本项经机构审查委员会批准、符合HIPAA的回顾性研究纳入51例多灶性双叶神经内分泌肿瘤肝转移并接受TACE的患者,在首次TACE前后于增强MRI上测量WHO、RECIST、mRECIST、EASL及全肝强化肿瘤负荷(ETB)指标。结果显示,ETB以30%、50%、65%为界值时分别有60.8%、39.2%、21.6%的患者出现反应,且是唯一与反应者与非反应者生存差异相关的生物标志物,50%界值模型最佳(HR 0.2,95%CI 0.1–0.4),多因素分析中ETB反应为独立生存预测因子(HR 0.2,95%CI 0.1–0.6)。

要点

  • 全肝强化肿瘤负荷(ETB)是首次TACE后早期反应生物标志物及生存替代指标。
  • ETB以50%为界值反应者与非反应者生存为84.3个月 vs 16.7个月(P<.01)。
  • 多因素分析中ETB反应为独立生存预测因子(HR 0.2,95%CI 0.1–0.6)。

核心结论

  • 容积ETB是多灶性双叶神经内分泌肿瘤肝转移患者首次TACE后的早期治疗反应生物标志物和生存替代指标。

研究设计与样本

  • 回顾性研究,符合HIPAA并经机构审查委员会批准,纳入51例多灶性双叶神经内分泌肿瘤肝转移接受TACE的患者,平均年龄57.8岁±13.2(范围13.5–85.8岁)。
  • 在基线和首次TACE后于增强MRI上测量最大面积(WHO)、最长直径(RECIST)、最长强化直径(mRECIST)、最大强化面积(EASL)及最大强化体积(ETB)。
  • ETB用三维软件测量,定义为高于正常肝实质感兴趣区信号强度2个标准差以上的区域。
  • 生存分析采用Kaplan-Meier曲线和Cox回归。
  • ETB反应界值(强化下降至少30%、50%、65%)通过Akaike信息准则分析确定。

诊断标准与关键数值

  • 治疗反应发生率:WHO标准5.9%、RECIST 2.0%、mRECIST 25.5%、EASL标准23.5%。
  • ETB反应率:30%界值60.8%、50%界值39.2%、65%界值21.6%。
  • ETB为唯一与反应者与非反应者生存差异相关的生物标志物:30%界值45.0个月 vs 10.0个月,50%界值84.3个月 vs 16.7个月,65%界值85.2个月 vs 21.2个月,P均<.01。
  • 50%界值提供最佳生存模型(HR 0.2,95%CI 0.1–0.4)。
  • 多因素分析中ETB反应为独立生存预测因子(HR 0.2,95%CI 0.1–0.6)。

临床应用与阅片要点

  • 原文结论认为容积ETB是首次TACE后早期治疗反应生物标志物及生存替代指标,可用于多灶性双叶神经内分泌肿瘤肝转移患者的疗效评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To investigate whether whole-liver enhancing tumor burden [ETB] can serve as an imaging biomarker and help predict survival better than World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and European Association for the Study of the Liver (EASL) methods in patients with multifocal, bilobar neuroendocrine liver metastases (NELM) after the first transarterial chemoembolization (TACE) procedure. Materials and Methods This HIPAA-compliant, institutional review board-approved retrospective study included 51 patients (mean age, 57.8 years ± 13.2; range, 13.5-85.8 years) with multifocal, bilobar NELM treated with TACE. The largest area (WHO), longest diameter (RECIST), longest enhancing diameter (mRECIST), largest enhancing area (EASL), and largest enhancing volume (ETB) were measured at baseline and after the first TACE on contrast material-enhanced magnetic resonance images. With three-dimensional software, ETB was measured as more than 2 standard deviations the signal intensity of a region of interest in normal liver. Response was assessed with WHO, RECIST, mRECIST, and EASL methods according to their respective criteria. For ETB response, a decrease in enhancement of at least 30%, 50%, and 65% was analyzed by using the Akaike information criterion. Survival analysis included Kaplan-Meier curves and Cox regressions. Results Treatment response occurred in 5.9% (WHO criteria), 2.0% (RECIST), 25.5% (mRECIST), and 23.5% (EASL criteria) of patients. With 30%, 50%, and 65% cutoffs, ETB response was seen in 60.8%, 39.2%, and 21.6% of patients, respectively, and was the only biomarker associated with a survival difference between responders and nonresponders (45.0 months vs 10.0 months, 84.3 months vs 16.7 months, and 85.2 months vs 21.2 months, respectively; P < .01 for all). The 50% cutoff provided the best survival model (hazard ratio [HR]: 0.2; 95% confidence interval [CI]: 0.1, 0.4). At multivariate analysis, ETB response was an independent predictor of survival (HR: 0.2; 95% CI: 0.1, 0.6). Conclusion Volumetric ETB is an early treatment response biomarker and surrogate for survival in patients with multifocal, bilobar NELM after the first TACE procedure. © RSNA, 2016.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Sahu S, Schernthaner R, Ardon R, et al. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology. 2016. PMID: 27831830. doi:10.1148/radiol.2016160838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。